CoChat

Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial

Open access
Kovatchev, Boris P, Kollar, Laura, Anderson, Stacey M, Barnett, Charlotte, Breton, Marc D, Carr, Kelly, Gildersleeve, Rachel, Oliveri, Mary C, Wakeman, Christian A, Brown, Sue A · 2020 · The Lancet Digital Health
Cited by 47

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background Automated closed-loop control delivery of insulin, also known as the artificial pancreas, is emerging as a treatment option for type 1 diabetes, which is considered generally superior to sensor-augmented insulin pump therapy. Evening and overnight closed-loop control might account for most of the benefits of 24/7 continuous closed-loop control; however, to our knowledge, no direct comparison of these systems has yet been done. In this study, we sought to compare different configurations of a closed-loop control system with activation of automated insulin delivery during the evening and overnight hours compared with continuous 24/7 closed-loop control, and both treatment modalities compared with sensor-augmented insulin pump use. Methods In this randomised crossover trial at the University of Virginia (Charlottesville, VA, USA), we randomly assigned (1:1) participants aged 18 to up to 70 years with a diagnosis of type 1 diabetes for at least 1 year to one of two sequences of four 8-week treatment sessions: sensor-augmented insulin pump therapy, evening and overnight closed-loop control, continuous 24/7 closed-loop control, and evening and overnight closed-loop control (group A) or evening and overnight closed-loop control, continuous 24/7 closed-loop control, evening and overnight closed-loop control, and sensor-augmented pump therapy (group B). Randomisation was done by non-clinical study staff using a computer-generated sequence of Bernoulli trials. The primary outcome of the study was the difference in the percentage of time continuous glucose monitored glucose was less than 3·9 mmol/L (70 mg/dL) during sensor-augmented pump therapy compared with evening and overnight closed-loop control. Our overall analysis followed a modified intention-to-treat approach, with all available data for participants who had completed at least two study sessions included in the analysis, regardless of actual use of a closed-loop control device. The trial was registered with ClinicalTrials.gov, NCT02679287. Findings Between April 21, 2016, and June 1, 2018, we assessed 103 patients for eligibility and 93 were randomly assigned to group A (n=47) or group B (n=46). Our final analysis included 80 participants who had completed at least two study phases (40 in group A and 40 in group B). Compared with sensor-augmented pump therapy sessions, evening and overnight closed-loop control sessions reduced the mean overall (day and night) percentage of time blood glucose was less than 70 mg/dL (3·9 mmol/L) from 4·0% (SD 3·3) to 2·2% (1·8), an absolute difference of −1·8% (95% CI 1·2–2·4; p<0·0001). This was accompanied by an overall reduction in HbA 1c from mean 7·4% (SD 1·0) at baseline to 7·1% (0·9) at the end of the study, resulting in an absolute difference of −0·3% (95% CI 0·1–0·4%; p<0·0001). We observed no cases of diabetic ketoacidosis. There were three cases of hyperglycaemia with ketosis that did not meet the criteria for diabetic ketoacidosis, all of which were treated at home with insulin and oral fluid, without known malfunction of the investigational device. There were five cases of severe hypoglycaemia attributed to user-directed boluses without malfunction of the investigational device. Interpretation In type 1 diabetes, evening and overnight closed-loop control was superior to sensor-augmented pump therapy, achieving most of the glycaemic benefits of 24/7 continuous closed-loop control. Our findings could offer people with type 1 diabetes more flexibility in treatment options with use of automated insulin delivery systems at varying times of day. Funding National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases. Roche, Tandem Diabetes Care, and Dexcom provided material support.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2589-7500(19)30218-3

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 47

Metadata

Authors
Kovatchev, B. P., Kollar, L., Anderson, S. M., Barnett, C., Breton, M. D., Carr, K., Gildersleeve, R., Oliveri, M. C., Wakeman, C. A., & Brown, S. A.
Venue
The Lancet Digital Health
Publisher
Elsevier BV
Published
2020-02
Volume
2
Issue
2
Pages
e64-e73
ISSN
2589-7500 (ISSN-L)
OpenAlex
W2998526207
Cited by
47
References
17
FWCI
5.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial. https://app.cochat.ai/papers/10.1016/s2589-7500(19)30218-3
The paper
Kovatchev, B. P., Kollar, L., Anderson, S. M., Barnett, C., Breton, M. D., Carr, K., Gildersleeve, R., Oliveri, M. C., Wakeman, C. A., & Brown, S. A. (2020). Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial. The Lancet Digital Health. https://doi.org/10.1016/s2589-7500(19)30218-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.